Peer-reviewedCC BY-NC-NDInternal Medicine
The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System Involvement
Abstract
Multiple myeloma with central nervous system (CNS) involvement is rare and associated with a poor prognosis. Although the emergence of novel therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies, has made it possible to obtain long-term disease control in multiple myeloma, there is still no established standard treatment for cases with CNS involvement, and the efficacy of novel therapies remains unclear. To our knowledge, we herein report the first case of successful elranatamab treatment in Japan in a patient with refractory multiple myeloma showing impaired consciousness caused by CNS involvement.
Related
- Efficacy analysis and adverse event management of selinexor in the treatment of relapsed/refractory multiple myeloma.
- Relapsing Polychondritis With Severe Airway Involvement Mimicking Refractory Asthma: A Diagnostic Challenge
- Refractory rapidly progressive diffuse in-stent restenosis with left main involvement: a case report.
- Effectiveness and safety of treatments for new-onset, refractory and relapsed vitreoretinal lymphoma: protocol for a systematic review and network meta-analysis.
- Prognostic value of simultaneous [18F]FDG‐PET/MRI in refractory multiple myeloma treated with anti‐BCMA CAR T
BibTeX
@article{uemura2026effectiveness,
title = {{The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System Involvement}},
author = {Misaki Uemura and Atsushi Marumo and Atsushi Obata and Nana Matsumoto and Meya Li and Yuta Kaito and Yasunobu Nagata and Satoshi Wakita and Hideto Tamura and Hiroki Yamaguchi},
journal = {Internal Medicine},
year = {2026},
month = aug,
doi = {10.2169/internalmedicine.6418-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/16/65_6418-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System Involvement
AU - Misaki Uemura
AU - Atsushi Marumo
AU - Atsushi Obata
AU - Nana Matsumoto
AU - Meya Li
AU - Yuta Kaito
AU - Yasunobu Nagata
AU - Satoshi Wakita
AU - Hideto Tamura
AU - Hiroki Yamaguchi
PY - 2026
DA - 2026/08/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.6418-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/16/65_6418-25/_article
AB - Multiple myeloma with central nervous system (CNS) involvement is rare and associated with a poor prognosis. Although the emergence of novel therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies, has made it possible to obtain long-term disease control in multiple myeloma, there is still no established standard treatment for cases with CNS involvement, and the efficacy of novel therapies remains unclear. To our knowledge, we herein report the first case of successful elranatamab treatment in Japan in a patient with refractory multiple myeloma showing impaired consciousness caused by CNS involvement.
SN - 1349-7235
SN - 0918-2918
ER -